Publicacións en colaboración con investigadores/as de Hospital Universitario de Canarias (142)

2024

  1. Combined use of QRISK3 and SCORE2 increases identification of ankylosing spondylitis patients at high cardiovascular risk: Results from the CARMA Project cohort after 7.5 years of follow-up

    Seminars in Arthritis and Rheumatism, Vol. 66

  2. Early identification of golimumab-treated patients with higher likelihood of long-term retention

    Frontiers in Immunology, Vol. 15

  3. Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature

    Arthritis Research and Therapy, Vol. 26, Núm. 1

  4. Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry

    Arthritis Research and Therapy, Vol. 26, Núm. 1

  5. Malondialdehyde Serum Levels in a Full Characterized Series of 430 Rheumatoid Arthritis Patients

    Journal of Clinical Medicine, Vol. 13, Núm. 3

  6. Mean Platelet Volume Is Related to Cumulative Disease Damage in Patients with Systemic Lupus Erythematosus

    Life, Vol. 14, Núm. 4

  7. Metabolic Syndrome: A Predisposing Factor for Rheumatoid Arthritis

    Journal of Rheumatology

  8. Relationship of Hematological Profiles with the Serum Complement System in Patients with Systemic Lupus Erythematosus

    Biomedicines, Vol. 12, Núm. 5

  9. SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort

    Lupus Science and Medicine, Vol. 11, Núm. 1

  10. The complement system is linked to insulin resistance in patients with systemic lupus erythematosus

    Clinical and experimental rheumatology, Vol. 42, Núm. 1, pp. 115-121

  11. Use of risk chart algorithms for the identification of psoriatic arthritis patients at high risk for cardiovascular disease: findings derived from the project CARMA cohort after a 7.5-year follow-up period

    RMD open, Vol. 10, Núm. 2